A mild symptom was bothering a young dad. He had Stage IV lung cancer.
“Endurance athlete Kevin Humphrey was used to discomfort. He regularly participated in ultramarathons and other intense events. Swimming, biking and running dozens of miles at a time was standard for him. His two young sons also kept him active even when he wasn’t training. But in January 2024, a persistent back pain kept bothering him.”
Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC
“Combining dendritic cell (DC) vaccination with atezolizumab (Tecentriq) produced long-term survival in a small cohort of patients with extensive-stage small cell lung cancer (ES-SCLC), according to findings from a phase 1b/2 trial (NCT04487756) presented in a poster session at the Society for Immunotherapy of Cancer 2025 Annual Meeting.”
The role of chronic obstructive pulmonary disease mediated by immune cells on lung adenocarcinoma: A two-step, two-sample Mendelian randomization study
“Chronic obstructive pulmonary disease (COPD) commonly co-occurs with lung cancer, particularly lung adenocarcinoma (LUAD), suggesting a potential shared molecular mechanism and risk factors between the 2 conditions. This study aimed to explore the causal relationship between COPD and LUAD mediated by immune cells using a 2-step, 2-sample Mendelian randomization (MR) analysis.”
Organ-based tumor distribution for predicting prognosis in small-cell lung cancer using fluorodeoxyglucose positron emission tomography/computed tomography
“To validate and compare conventional metabolic tumor burden measurements with comprehensive metabolic tumor distribution patterns using [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) to predict small-cell lung cancer (SCLC) prognosis.”
Aging represses oncogenic KRAS-driven lung tumorigenesis and alters tumor suppression
“Most cancers are diagnosed in people over 60 years of age, but little is known about how age impacts tumorigenesis. While aging is accompanied by mutation accumulation (widely understood to contribute to cancer risk) it is associated with numerous other cellular and molecular changes likely to impact tumorigenesis. Moreover, cancer incidence decreases in the oldest part of the population, suggesting that very old age may reduce carcinogenesis.”
The lung cancer-associated blood biomarker hPG80 exhibits a reversible increase in response to smoking in asymptomatic individuals
“The blood biomarker hPG80 is linked to multiple solid tumors, including lung cancer. This study examined blood hPG80 levels of asymptomatic individuals and patients with non-small cell lung cancer (NSCLC), categorized by their smoking and chronic obstructive pulmonary disease (COPD) status.”
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
“Resistance to EGFR tyrosine kinase inhibitors (TKIs) remains a major obstacle in the clinical management of EGFR-mutant non-small-cell lung cancer (NSCLC). Despite the transformative therapeutic activity of the multiple iterations of EGFR TKIs, spanning from first-generation reversible inhibitors such as erlotinib and gefitinib to the current standard-of-care third-generation covalent inhibitor osimertinib, primary or acquired resistance to these agents inevitably emerges via diverse mechanisms.”
Arkansas’s Lung Cancer Rate Among Highest in U.S., 2025 Report Finds
“The 2025 “State of Lung Cancer” report finds that Arkansas’s rate of new lung cancer cases is 68.2 cases per 100,000 people. Arkansas is ranked 47th among the 50 states and the District of Columbia for this measure; in this and all other measures, the No. 1 state has the best rate and the No. 51 state has the worst. Arkansas’s rate of new cases is significantly higher than the national rate of 52.8 cases per 100,000 people.”
‘An Incredible Response’: A Clinical Trial at the CU Cancer Center Successfully Treated Jennifer Brown’s Stage IV Lung Cancer
“Tejas Patil, MD, enrolled Brown in the trial of the drug that shrank her liver metastases by 50% within weeks.”
The world’s first trial of a vaccine to prevent lung cancer
“In a world-first clinical trial, our scientists will begin testing an experimental vaccine designed to prevent lung cancer in people at high risk of the disease.”
Targeting Inflammation Could Halt Lung Cancer Before It Starts
“By creating high-resolution cellular and molecular visual maps of lung cancer before and during development, researchers at The University of Texas MD Anderson Cancer Center have discovered that the earliest stages of lung cancer may be driven by inflammation, suggesting that targeting proinflammatory pathways could be an early intervention approach.”
Boehringer awarded FDA Commissioner’s National Priority Voucher for zongertinib in patients with HER2-mutant NSCLC
“Boehringer Ingelheim today confirmed that the U.S. Food & Drug Administration (FDA) has awarded a Commissioner’s National Priority Voucher (CNPV) to zongertinib for the treatment of patients with HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC). This recognition underscores the potential of zongertinib to meet critical patient needs for this rare and aggressive cancer.”
Synthekine reports initial STK-012 data in lung cancer trial
“The therapy, when combined with SoC PCT, exhibited encouraging efficacy and safety outcomes.”
Eosinophilia Linked With Immune-Related Adverse Events in NSCLC Treatment
“Key Takeaways: Pretreatment eosinophilia in NSCLC patients is associated with increased immune-related adverse events and reduced progression-free survival when treated with ICIs. The review included 11 retrospective cohort studies with 14,095 individuals, highlighting eosinophilia as a potential prognostic biomarker.”
